|
Test pvFPGc (mmol/l)
|
cFBGd (mmol/l)
|
Occurrence n = 3616 (%)
|
Sensitivity (%)
|
Specificity (%)
|
PPVe (%)
|
NPVf (%)
|
AUCg (%)
|
|---|
|
A.
|
|
≥ 4.4
|
(4.0)
|
49
|
96 (94–98)
|
57 (55–59)
|
23 (21–25)
|
99 (98–99)
|
77 (75–78)
|
|
≥ 4.6
|
(4.1)
|
41
|
95 (93–97)
|
67 (65–68)
|
28 (25–30)
|
99 (99–99)
|
81 (79–83)
|
|
≥ 4.8
|
(4.3)
|
24
|
91 (88–94)
|
85 (83–86)
|
44 (41–48)
|
99 (98–99)
|
88 (86–90)
|
|
≥ 5.0
|
(4.5)
|
14
|
89 (86–92)
|
96 (95–96)
|
73 (69–77)
|
99 (98–99)
|
92 (91–94)
|
|
Traditional risk factorsh
|
16
|
28 (24–32)
|
86 (84–87)
|
20 (17–24)
|
90 (89–91)
|
43 (40–46)
|
|
Traditional risk factorsh or RBGi ≥8.0 (mmol/l)
|
19
|
36 (32–41)
|
84 (82–85)
|
23 (20–26)
|
91 (90–92)
|
40 (37–43)
|
|
B.
|
|
≥ 4.4
|
(4.0)
|
49
|
96 (93–98)
|
54 (53–56)
|
14 (12–16)
|
99 (99–100)
|
75 (73–78)
|
|
≥ 4.6
|
(4.1)
|
41
|
96 (93–98)
|
64 (62–65)
|
17 (15–19)
|
100 (99–100)
|
80 (78–82)
|
|
≥ 4.8
|
(4.3)
|
24
|
93 (89–95)
|
81 (80–82)
|
28 (25–31)
|
99 (99–100)
|
87 (85–89)
|
|
≥ 5.0
|
(4.5)
|
14
|
91 (87–94)
|
92 (91–93)
|
46 (42–50)
|
99 (99–100)
|
91 (89–94)
|
|
≥ 5.2
|
(4.7)
|
8
|
89 (84–92)
|
98 (98–99)
|
78 (73–83)
|
99 (99–99)
|
94 (91–96)
|
|
Traditional risk factorsh
|
16
|
31 (25–37)
|
85 (84–86)
|
14 (11–17)
|
94 (93–95)
|
42 (38–46)
|
|
Traditional risk factorsh or RBGi ≥ 8.0 (mmol/l)
|
19
|
41 (35–47)
|
83 (82–84)
|
16 (13–19)
|
95 (94–96)
|
38 (34–42)
|
- aModel I: Modified IADPSG criteria, 1.75 OR, equivalent cFBG ≥4.6 mmol/l or 2 h OGTT ≥8.5 mmol/l
- bModel II: HAPO data 2.0 OR, equivalent cFBG ≥4.8 mmol/l or 2 h OGTT ≥9.0 mmol/l
- cpvFPG Predicted venous fasting plasma glucose, equivalent cFBG value with conversion factor 1.11
- dcFBG capillary fasting blood glucose
- ePPV positive predictive value
- fNPV negative predictive value
- gAUC area under the curve
- hTraditional risk factors = heredity (first-degree relative), obesity [≥ 90 kg, pre-pregnancy weight], previous LGA infant [≥ 4500 g or ≥ mean + 2SD], previous GDM
- iRBG = random blood glucose
